Решение проблемы нарушенного микробиоценоза у детей с синдромом раздраженного кишечника


DOI: https://dx.doi.org/10.18565/pharmateca.2019.1.70-76

Н.И. Урсова

Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского, Москва, Россия
Терапия современными пробиотиками приобретает особое значение практически при любых острых и хронических заболеваниях, сопровождающихся дисфункцией микробиоценоза и кишечного барьера. В статье приводятся данные о роли микробных сообществ в развитии синдрома раздраженного кишечника. Необходимость применения пробиотиков остается более чем актуальной ввиду их эффективности, безопасности и широкой доступности. Представлены результаты исследований с использованием штамма Lactobacillus rhamnosus в разнообразных клинических ситуациях.
Ключевые слова: синдром раздраженного кишечника, Римский консенсус-IV, микробиоценоз, Lactobacillus rhamnosus, дети

Литература


1. Drossman D.A., Chang L., et al. Rome IV, functional gastrointestinal disorders, disorders of gut-brain interaction. Fouth, The Rome Foundation, Raleigh (NC). 2016.

2. Filipovic B., Forbes A., Tepes B. Current approaches to the functional gastrointestinal disorders. Gastroenterol Res Pract 2017;2017:4957154. Doi: 10.1155/2017/4957154.

3. Drossman D.A. Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology. 2016;150(6):1262–79. Doi: 10.1053/j.gastro.2016.02.032.

4. Lacy B.E., Mearin F., Chang L., et al. Bowel disorders. Gastroenterology. 2016;150:1393–407. Doi: 10.1053/j.gastro.2016.02.031.

5. Carabotti M., Scirocco A., Maselli M.A., Severi C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol 1015;28:203–25.

6. Phipott H., Gibson P., Thien F. Irritable bowel syndrome – an inflammatory disease involving mast cell. Asia Pac Allergy. 2011;1(1):36–42. Doi: 10.5415/apallergy.2011.1.1.36.

7. Kennedy P.J., Cryan J.F., Dinan T.G., Clarke G. Irritable bowel syndrome: a microbiome-gut-brain axis disorder? World J Gastroenterol. 2014;20(39):14105–25. Doi: 10.3748/wjg.v20.i39.14105.

8. Kovacic K. Current concepts in functional gastrointestinal disorders. Curr Opin Pediatr. 2015;27(5):619–24. Doi: 10.1097/MOP.0000000000000262.

9. De Palma G., Collins S.M., Bercik P., Verdu E.F. The microbiota-gut-brain axis in gastrointestinal disorders: stressed bugs, stressed brain or both? J Physiol. 2014;592:2989–97. Doi: 10.1113/jphysiol.2014.273995.

10. Clarke G., Grenham S., Scully P., et al. The microbiome-gut-brain axis during early life regulates the hippocampal serotonengic system in a sex-dependent manner. Mol Psychiatry. 2013;18(6):666–73. Doi: 10.1038/mp.2012.77.

11. Yu L.C., Wang Jt., Wei S.C., Ni Y.H. Host-microbial interactions and regulation of intestinal epithelial barrier function: From physiology to pathology. World J Gastrointest Pathophysiol. 2012;3(1):27–43. Doi: 10.4291/wjgp.v3.i1.27.

12. Shafquat A., Joice R., Simmons S.L., Huttenhower C. Functional and phylogenetic assembly of microbial communities in the human microbiome. Trends Microbiol. 2014;22(5):261–66. Doi: 10.1016/j.tim.2014.01.011.

13. Cullen T.W., Schofield W.B., Barry N.A., et al. Gut microbiota. Antimicrobial peptide resistance mediates resilience of prominent gut commensals during inflammation. Science. 2015;347(6218):170–75. Doi: 10.1126/science.1260580.

14. Magnusdottir S., Ravcheev D., de Crecy-Lagard V.,Thiele I. Systematic genome assessment of B-vitamin biosynthesis suggests co-operation among gut microbes. Front Genet 2015;6:148. Doi: 10.3389/fgene.2015.00148.

15. Neis E.P., Dejong C.H., Rensen S.S. The role of microbial amino acid metabolism in host metabolism. Nutrients. 2015;7(4):2930–46. Doi: 10.3390/nu7042930.

16. Sagar N.M., Gree I.A., Covington J.A., Arasaradnam R.P. The interplay of the gut microbiome, bile acids, and volatile organic compounds. Gastroenterol Res Pract. 2015;2015:398585. Doi: 10.1155/2015/398585.

17. Pozuelo M., Panda S., Santiago A., et al. Reduction of butyrate- and methane-producing microorganisms in patients with irritable bowel syndrome. Sci Rep. 2015;5:12693. Doi: 10.1038/srep12693.

18. Ford A.C., Spiegel B.M., Talley N.J., Moaguedi P. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2009;7:1279–86. Doi: 10.1016/j.cgh.2009.06.031.

19. Shelley H., Brennan M., Heuschkel R. Hydrogen breath testing in children: what is it and why is it performed? Castroint Nurs. 2009;7:18–27.

20. Lozupone C.A., Stombaugh J.I., Gordon Ji., et al. Diversity, stability and resilience of the human gut microbiota. Nature 2012;489(7415):220–30. Doi: 10.1038/nature11550

21. Dore J., Corthier G. The human intestinal microbiota. Gastroenterol Clin Biol. 2010;34:7–15. Doi: 10.1016/S0399-8320(10)70015-4.

22. Salonen A., Salojarvi J., Lahti L., de Vos W.M. The adult intestinal core microbiota is determined by analysis depth and health status. Clin Microbiol Infect. 2012;18(4):16–20. Doi: 10.1111/j.1469-0691.2012.03855.x.

23. Hemarajata P., Versalovic J. Effect of probiotics on gut microbiota: mechanisms of intestinal immunomodulation and neuromodulation. Therap Adv Gastroenterol. 2013;6(1):39-51. Doi: 10.1177/1756283X12459294.

24. Whelan K., Quigley E.M. Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease. Curr Opin Gastroenterol. 2013;29(2):184–89. Doi: 10.1097/MOG.0b013e32835d7bba.

25. Moayyedi P., Ford A.C., Talley N.J., et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: asystematic review. Gut. 2010;59(3):325–32.

26. Mercenier A., Pavan S., Pot B. Probiotics as biotherapeutic agent: present khuwledge and future prospects. Curr Pharm Des. 2003;9:175–91.

27. Timmerman H.M., Koning C.J.M., Mulder L., et al. Monostrain, multistrain and multispecies probiotics. A comparison of functionality and efficacy. Int J Food Microbiol. 2004;96:219–33.

28. Medzhitov R. Toll-like receptors and innate immunity. Nature Reviews Immunology. 2001;1(2):143–45.

29. Walter J. Ecological role of lactobacilli in the gastrointestinal tract: implication for fundamental and biomedical research. Appl Envir Microbiol. 2008;74(16):4985–96.

30. Vinderola G., Matar C., Perdigon G. Role of intestinal epithelial cells in immune effects mediated by gram-positive probiotic bacteria: involvement of toll-like receptors. Clin Diagn Lab Immunol. 2005;12(9):1075–84.

31. Vesikari T., Uhari M., Renko M., et al. Impact and effectiveness of RotaTeq® vaccine based on 3 years of surveillance following introduction of rotavirus immunization program in Finland. Pediatr Infect Dis J. 2013;32(12):1365–73. Doi: 10.1097/INF.0000000000000086.

32. Szajewska H., Mrukowicz J. Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo controlled trials. J Pediatr Gastroenterol Nutr. 2001;33:17–25.

33. Bezkorovainy A. Probiotics: determinants of survival and growth in the gut. Am J Clin Nutr. 2001;73:399–405. Doi: 10.1093/ajcn/73.2.399s.

34. Guarino A., Albano F., Ashkenazi Sh., et al. European Society for Paediatric Gastroenterology, Hepatology, and Nutrition/European Society for Paediatric Infectious Diseases Evidence-based Guidelines for the Management of Acute Gastroeteritis in Children in Europe. J of Pediatric Gastroenterology and Nutrition. 2008;46:81–184.

35. Roberfroid M. Prebiotics: the concept revisited. J Nutr. 2007;137(3):830–37. Doi: 10.1093/jn/137.3.830S.

36. Roberfroid M., Robertson D. Effect of inulin and oligofructose on health and well-being. Brit J Nutr. 2005;9(1):1–27.

37. Floch M.H., Walker W.A., Sanders M., et al. Recommendation for Probiotic Use – 2015 Update: Proceedings and consensus Opinion. J Clin Gastroenterol. 2015;49(1):69–73. Doi: 10.1097/MCG.0000000000000420.

38. Horvath A., Dziechciarz P., Szayewska H. Meta-analysis: Lactobacillus rhamnosus GG in functional gastrointestinal disoders associated with abdominal pain in childhood. Alimentary Pharmacology and Therapeutics. 2013;3:1302–10. Doi: 10.1111/j.1365-2036.2011.04665.x.

39. Hojsak I., Snovak N., Abdovic S., et al. Lactobacillus GG in the prevention og gastrointestinal and respiratory tract infections in children who attend care centers a randomized, double-blind, placebo controlled trial. Clin Nutr. 2010;29(3):312–16.

40. Kianifar H., Jafari S.A., Kiani M., et al. Probiotic for irritable bower syndrome in pediatrics patients a randomized controlled clinical trial. Electron Physician. 2015;7(5):1255–60. Doi: 10.14661/1255.

41. Derrien M., van Hylckama Vieg J.E.T. Fate, activity, and impact of ingested bacteria within the human gut microbiota. Trends Microbiol. 2015;23(6):354–66. Doi: 10.1016/j.tim.2015.03.002.

42. Sanders M.E. Impact of probiotics on colonizing microbiota of the gut. J Clin Gastroenterol. 2011;45(3):115–19. Doi: 10.1097/MCG.0b013e318227414a.

43. Martens U., Enck P., Zieseniss P. Probiotic treatment of irritable bowel syndrome in children. Ger Med Sci. 2010;8:1–15. Doi: 10.3205/000096.

44. Quigley E.M., Abdel-Hamid H., Barbara G., et al. A global perspective on irritable bowel syndrome: a consensus statement of the World Gastroenterology Organisation Summit Task Force on irritable bowel syndrome. J Clin Gastroenterol. 2012;46(5):356–66. Doi: 10.1097/MCG.0b013e318247157c.

45. Simren M., Barbara G., Flint H.J., et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. 2013;62(1):159–76. Doi: 10.1136/gutjnl-2012-302167.

46. Cruchet S., Furnes R., Maruy A., et al. The use of probiotics in pediatric gastroenterology: a review of the literature and recommendations by latin-american experts. Paediatr Drugs. 2015;17(3):199–216. Doi: 10.1007/s40272-015-0124-6.


Об авторах / Для корреспонденции


Автор для связи: Н.И. Урсова, д.м.н., проф., рук. педиатрической клиники МОНИКИ им. М.Ф. Владимирского, зав. кафедрой педиатрии ФУВ МОНИКИ, Москва, Россия; тел. +7 (495) 681-25-98
Адрес: 129110, Россия, Москва, ул. Щепкина, 61/2, корп. 1


Бионика Медиа